Functional Genomics of the Paraoxonase (PON1) Polymorphisms: Effects on Pesticide Sensitivity, Cardiovascular Disease, and Drug Metabolism

Annual Review of Medicine

Volumn 54, Issue , 2003, Pages 371-392

  Costa, Lucio G ^a   Cole, Toby B ^a,b   Jarvik, Gail P ^b   Furlong, Clement E ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Drug metabolism; Linkage disequilibrium; Metabolism of oxidized lipids; Nerve agents; Organophosphate metabolism; Statin metabolism

Indexed keywords

2 PIPERIDONE; ARGININE; ARYLDIALKYLPHOSPHATASE; CADMIUM; CAPROLACTAM; CARBONIC ACID DERIVATIVE; CHLORPYRIFOS; COMPACTIN; DIMPYLATE; EDETIC ACID; GLYCINE; INSECTICIDE; IRON; KB 4 4899; LACTONE DERIVATIVE; MERCURY CHLORIDE; METHYLMERCURY; MEVINOLIN; ORGANOPHOSPHATE INSECTICIDE; PESTICIDE; PHENOBARBITAL; PRAVASTATIN; PRULIFLOXACIN; SIMVASTATIN; UNCLASSIFIED DRUG; ZINC; ESTERASE; ORGANOPHOSPHORUS COMPOUND; PON1 PROTEIN, HUMAN;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHEMOSENSITIVITY; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG METABOLISM; ENZYME POLYMORPHISM; GENE FUNCTION; GENETIC VARIABILITY; HUMAN; PESTICIDE SPRAYING; PON1 GENE; PRIORITY JOURNAL; PROTEIN ANALYSIS; REVIEW; ANIMAL; CAROTID ARTERY OBSTRUCTION; CHROMOSOME 7; CHROMOSOME MAP; CORONARY ARTERY ATHEROSCLEROSIS; DRUG DETOXIFICATION; ETHNIC GROUP; GENE LINKAGE DISEQUILIBRIUM; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; METABOLISM; RISK FACTOR;

ANIMALS; ARYLDIALKYLPHOSPHATASE; CAROTID STENOSIS; CHROMOSOME MAPPING; CHROMOSOMES, HUMAN, PAIR 7; CORONARY ARTERIOSCLEROSIS; ESTERASES; ETHNIC GROUPS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INSECTICIDES; LINKAGE DISEQUILIBRIUM; METABOLIC DETOXICATION, DRUG; ORGANOPHOSPHORUS COMPOUNDS; POLYMORPHISM, GENETIC; RISK FACTORS;

EID: 0037639963     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.54.101601.152421     Document Type: Review

References (134)

1. Durrington PN, Mackness B, Mackness MJ. 2001. Paraoxonase and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 21:473-80
2. Costa LG, Li WF, Richter RJ, et al. 2002. PON1 and organophosphate toxicity. See Ref. 2a, pp. 165-83
3. 2a. Costa LG, Furlong CE. 2002. Paraoxonase (PON1) in Health and Disease: Basic and Clinical Aspects. Norwell, MA: Kluwer Acad.
4. Eckerson HW, White CM, La Du BN. 1983. The human serum paraoxonase/ arylesterase polymorphism. Am. J. Hum. Genet. 35:1126-38
5. Mueller RF, Hornung S, Furlong CE, et al. 1983. Plasma paraoxonase polymorphism: a new enzyme assay, population, family, biochemical and linkage studies. Am. J. Hum. Genet. 35:393-408
6. Geldmacher-Von Mallinckrodt M, Diepgen TL. 1988. The human serum paraoxonase polymorphism and specificity. Toxicol. Environ. Chem. 18:79-196
7. Hassett C, Richter RJ, Humbert R, et al. 1991. Characterization of DNA clones encoding rabbit and human serum paraoxonase: the mature protein retains its signal sequence. Biochemistry 30:10141-49
8. Leviev I, James RW. 2000. Promoter polymorphisms of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations. Arterioscler. Thromb. Vasc. Biol. 20:516-21
9. Suehiro T, Nakamura T, Inoue M, et al. 2000. A polymorphism upstream from the human paraoxonase (PON1) gene and its association with PON1 expression. Atherosclerosis 150:295-98
10. Brophy VM, Hastings MD, Clendenning JB, et al. 2001. Polymorphisms in the human paraoxonase (PON1) promoter. Pharmacogenetics 11:77-84
11. Brophy VH, Jampsa RL, Clendenning JB, et al. 2001. Effects of 5′ regulatory-region polymorphisms on paraoxonase-gene (PON1) expression. Am. J. Hum. Genet. 68:1428-36
12. Brophy VH, Jarvik GP, Furlong CE. 2002. PON1 polymorphisms. See Ref. 2a, pp. 53-77
13. Smolen A, Eckerson HW, Gan K, et al. 1991. Characteristics of the genetically determined polymorphic forms of human serum paraoxonase/ arylesterase. Drug. Metab. Disp. 19:107-12
14. Adkins S, Gan KN, Mody M, et al. 1993. Molecular basis for the polymorphic forms of human serum paraoxonase/ arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. Am. J. Hum. Genet. 53:598-608
15. Humbert R, Adler DA, Disteche CM, et al. 1993. The molecular basis of the human serum paraoxonase activity polymorphism. Nat. Genet. 3:73-76
16. Davies HG, Richter RJ, Keifer M, et al. 1996. The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. Nat. Genet. 14:334-36
17. Li WF, Costa LG, Richter RJ, et al. 2000. Catalytic efficiency determines the in vivo efficacy of PON1 for detoxifying organophosphates. Pharmacogenetics 10:1-13
18. Deleted in proof
19. Gan KN, Smolen A, Eckerson HW, et al. 1991. Purification of human serum paraoxonase/arylesterase. Evidence for one esterase catalyzing both activities. Drug Metab. Dispos. 19:100-6
20. Sorenson RC, Bisgaier CL, Aviram M, et al. 1999. Human serum paraoxonase/ arylesterase's retained hydrophobic N-terminal leader sequence associates with HDLs by binding phospholipids: apolipoprotein A-1 stabilizes activity. Arterioscler. Thromb. Vasc. Biol. 19: 2214-25
21. Blatter MC, James RW, Messmer S, et al. 1993. Identification of a distinct human high-density lipoprotein subspecies defined by a lipoprotein-associated protein, K-45. Identity of K-45 with paraoxonase. Eur. J. Biochem. 211:871-79
22. Deakin S, Leviev I, Gomaraschi M, et al. 2002. Enzymatically active paraoxonase-1 is located at the external membrane of producing cells and released by a high-affinity, saturable, desorption mechanism. J. Biol. Chem. 277(6):4301-8
23. Blatter Garin MC, James RW, Dussoix P, et al. 1997. Paraoxonase polymorphism Met-Leu 54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes. J. Clin. Invest. 99:62-66
24. Mackness B, Mackness MI, Arrol S, et al. 1998. Serum paraoxonase (PON1) 55 and 192 polymorphism and paraoxonase activity and concentration in non-insulin dependent diabetes mellitus. Atherosclerosis 139:341-49
25. Leviev I, Deakin S, James RW. 2001. Decreased stability of the M54 isoform of paraoxonase as a contributory factor to variations in human serum paraoxonase concentrations. J. Lipid Res. 42(4):528-35
26. Li WF, Costa LG, Furlong CE. 1993. Serum paraoxonase status: a major factor in determining resistance to organophosphates. J. Toxicol. Environ. Health 40: 337-46
27. Richter RJ, Furlong CE. 1999. Determination of paraoxonase (PON1) status requires more than genotyping. Pharmacogenetics 9:745-53
28. 55 genotype. Arterioscler. Thromb. Vasc. Biol. 20:2441-47
29. Lotti M. 2000. Organophosphorus compounds. In Experimental and Clinical Neurotoxicology, ed. PS Spencer, H Schaumburg, AC Ludolph, pp. 898-925. Oxford, UK: Oxford Univ. Press
30. Main AR. 1956. The role of A-esterase in the acute toxicity of paraoxon, TEPP and parathion. Can. J. Biochem. Physiol. 34:197-216
31. Brealey CB, Walker CH, Baldwin BC. 1980. A-Esterase activities in relation to the differential toxicity of pirimiphosmethyl to birds and mammals. Pestic. Sci. 11:546-54
32. Costa LG, Richter RJ, Murphy SD, et al. 1987. Species differences in serum paraoxonase correlate with sensitivity to paraoxon toxicity. In Toxicology of Pesticides: Experimental, Clinical and Regulatory Perspectives, ed. LG Costa, CL Galli, SD Murphy, pp. 262-66. Heidelberg: Springer-Verlag
33. Furlong CE, Richter RJ, Chapline C, et al. 1991. Purification of rabbit and human serum paraoxonase. Biochemistry 30:10133-40
34. Costa LG, McDonald BE, Murphy SD, et al. 1990. Serum paraoxonase and its influence on paraoxon and chlorpyrifos oxon toxicity in rats. Toxicol. Appl. Pharmacol. 103:66-76
35. Li WF, Furlong CE, Costa LG. 1995. Paraoxonase protects against chloropyrifos toxicity in mice. Toxicol. Lett. 76:219-26
36. Cowan J, Sinton CM, Varley AW, et al. 2001. Gene therapy to prevent organophosphate intoxication. Toxicol. Appl. Pharmacol. 173:1-6
37. Shih DM, Gu L, Xia YR, et al. 1998. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 394:284-98
38. Pond AL, Chambers HW, Chambers JE. 1995. Organophosphate detoxication potential of various rat tissues via A-esterases and aliesterase activities. Toxicol. Lett. 78:245-52
39. Chambers JE, Ma T, Boone JS, et al. 1994. Role of detoxication pathways in acute toxicity levels of phosphorothionate insecticides in the rat. Life Sci. 54:1357-64
40. Eskenazi B, Bradnam A, Castorina R. 1999. Exposure of children to organophosphate pesticides and their potential adverse health effects. Environ. Health. Perspect. 107(Suppl. 3):409-19
41. Benke GM, Murphy SD. 1975. The influence of age in the toxicity and metabolism of methylparathion and parathion in male and female rats. Toxicol. Appl. Pharmacol. 31:254-69
42. Pope CN, Liu J. 1997. Age-related difference in sensitivity to organophosphorus pesticides. Environ. Toxicol. Pharmacol. 4:309-14
43. Sheets LP. 2000. A consideration of age-dependent differences in susceptibility to organophosphorus and pyrethroid insecticides. NeuroToxicology 21:57-64
44. Dam K, Seidler FJ, Slotkin TA. 2000. Chlorpyrifos exposure during a critical neonatal period elicits gender-selective deficits in the development of coordination skills and locomotor activity. Dev. Brain Res. 121:179-87
45. Moretto A, Capodicasa E, Peraica M, et al. 1991. Age sensitivity to organophosphate-induced delayed polyneuropathy. Biochemical and toxicological studies in developing chicks. Biochem. Pharmacol. 10:1497-504
46. Mortensen SR, Chanda SM, Hooper MJ, et al. 1996. Maturational differences in chlorpyrifos-oxonase activity may contribute to age-related sensitivity to chlorpyrifos. J. Biochem. Toxicol. 11:279-87
47. Padilla S, Buzzard J, Moser VC. 2000. Comparison of the role of esterases in the differential age-related sensitivity to chlorpyrifos and metamidophos. Neuro-Toxicology 21:49-56
48. Li WF, Mathews C, Disteche CM, et al. 1997. Paraoxonase (PON1) gene in mice: sequencing, chromosomal localization and developmental expression. Pharmacogenetics 7:137-44
49. Augustinsson KB, Barr M. 1963. Age variation in plasma arylesterase activity in children. Clin. Chim. Acta 8:568-73
50. Augustinsson KB, Brody S. 1962. Plasma arylesterase activity in adults and newborn infants. Clin. Chim. Acta 7:560-65
51. Ecobichon DJ, Stephens DS. 1972. Perinatal development of human blood esterases. Clin. Pharmacol. Ther. 14:41-47
52. Lusis AJ. 2000. Atherosclerosis. Nature 407:233-41
53. Mackness MI, Arrol S, Abbott C, et al. 1993. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis 104:129-35
54. Noto H, Hashimoto Y, Satoh H, et al. 2001. Exclusive association of paraoxonase 1 with high-density lipoprotein particles in apolipoprotein A-I deficiency. Biochem. Biophys. Res. Commun. 289:395-401
55. Mackness MI, Arrol S, Durrington PN. 1991. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett. 286:152-54
56. Watson AD, Berliner JA, Hama SY, et al. 1995. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J. Clin. Invest. 96:2882-91
57. Mackness B, Mackness MI, Arrol S, et al. 1998. Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification. FEBS Lett. 423:57-60
58. Aviram M, Rosenblat M, Bisgaier CL, et al. 1998. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J. Clin. Invest. 101:1581-90
59. Aviram M, Billecke S, Sorenson R, et al. 1998. Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities: selective action of human paraoxonase allozymes Q and R. Arterioscler. Thromb. Vasc. Biol. 18:1617-24
60. Aviram M, Hardak E, Vaya J, et al. 2000. Human serum paraoxonases (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions: PON1 esterase and peroxidase-like activities. Circulation 101:2510-17
61. Navab M, Hama SY, Anantharamaiah GM, et al. 2000. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3. J. Lipid Res. 41:1495-508
62. Ahmed Z, Ravandi A, Maguire GF, et al. 2001. Apolipoprotein A-I promotes the formation of phosphatidylcholine core aldehydes that are hydrolyzed by paraoxonase (PON-1) during high density lipoprotein oxidation with a peroxynitrite donor. J. Biol. Chem. 276:24473-81
63. Navab M, Hama-Levy S, Van Lenten BJ, et al. 1997. Mildly oxidized LDL induces an increased apolipoprotein J/paraoxonase ratio. J. Clin. Invest. 99:2005-19
64. Castellani LW, Navab M, Lenten BJV, et al. 1997. Overexpression of apolipoprotein AII in transgenic mice converts high density lipoproteins to proinflammatory particles. J. Clin. Invest. 100:464-74
65. Mackness B, Durrington PN, Mackness MI. 1998. Lack of protection against oxidative modification of LDL by avian HDL. Biochem. Biophys. Res. Commun. 247:443-46
66. Shih DM, Xia YR, Wang XP, et al. 2000. Combined serum paraoxonase knockout/ apolipoprotein E knockout mice exhibit increased lipoprotein oxidation and atherosclerosis. J. Biol. Chem. 275: 17527-35
67. Shih DM, Reddy S, Lusis AJ. 2002. CHO and atherosclerosis: human epidemiological studies and transgenic mouse models. See Ref. 2a, pp. 93-123
68. Shih DM, Gu L, Hama S, et al. 1996. Genetic-dietary regulation of serum paraoxonase expression and its role in atherogenesis in a mouse model. J. Clin. Invest. 97:1630-39
69. Hedrick CC, Hassan K, Hough GP, et al. 2000. Short-term feeding of atherogenic diet to mice results in reduction of HDL and paraoxonase that may be mediated by an immune mechanism. Arterioscler. Thromb. Vasc. Biol. 20:1946-52
70. Van Lenten BJ, Wagner AC, Navab M, et al. 2001. Oxidized phospholipids induce changes in hepatic paraoxonase and ApoJ but not monocyte chemoattractant protein-1 via interleukin-6. J. Biol. Chem. 276:1923-29
71. Mackness B, Durrington PN, Mackness MI. 1999. Polymorphisms of paraoxonase genes and low-density lipoprotein lipid peroxidation. Lancet 353:468-69
72. Mackness B, Davies GK, Turkie W, et al. 2001. Paraoxonase status in coronary heart disease: Are activity and concentration more important than genotype? Arterioscler. Thromb. Vasc. Biol. 21:1451-57
73. Reddy ST, Wadleigh DJ, Grijalva V, et al. 2001. Human paraoxonase-3 is an HDL-associated enzyme with biological activity similar to paraoxonase-1 protein but is not regulated by oxidized lipids. Arterioscler. Thromb. Vasc. Biol. 21:542-47
74. Ng CJ, Wadleigh DJ, Gangopadhyay A, et al. 2001. Paraoxonase-2 is a ubiquitously expressed protein with antioxidant properties and is capable of preventing cell-mediated oxidative modification of low density lipoprotein. J. Biol. Chem. 276:44444-49
75. Ruiz J, Blanche H, James RW, et al. 1995. Gln-Arg192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes. Lancet 346:869-72
76. Serrato M, Marian AJ. 1995. A variant of human paraoxonase/arylesterase (HUMPONA) gene is a risk factor for coronary artery disease. J. Clin. Invest. 96:3005-8
77. Pfohl M, Koch M, Enderle MD, et al. 1999. Paraoxonase 192 Gln/Arg gene polymorphism, coronary artery disease, and myocardial infarction in type 2 diabetes. Diabetes 48:623-27
78. Zama T, Murata M, Matsubara Y, et al. 1997. A 192Arg variant of the human paraoxonase (HUMPONA) gene polymorphism is associated with an increased risk for coronary artery disease in the Japanese. Arterioscler. Thromb. Vasc. Biol. 17:3565-69
79. Sanghera D, Saha N, Aston CE, et al. 1997. Genetic polymorphism of paraoxonase and the risk of coronary heart disease. Arterioscler. Thromb. Vasc. Biol. 17:1067-73
80. Sanghera D, Aston CE, Saha N, et al. 1998. DNA polymorphisms in two paraoxonase genes (PON1 and PON2) are associated with the risk of coronary heart disease. Am. J. Hum. Genet. 62:36-44
81. Pati N, Pati U. 1998. Paraoxonase gene polymorphism and coronary artery disease in Indian subjects. Int. J. Cardiol. 66:165-68
82. Imai Y, Morita H, Kurihara H, et al. 2000. Evidence for association between paraoxonase gene polymorphisms and atherosclerotic diseases. Atherosclerosis 149:435-42
83. Heijsmans B, Westendorp RG, Lagaay AM, et al. 2000. Common paraoxonase gene variants, mortality risk and fatal cardiovascular events in elderly subjects. Atherosclerosis 149:91-97
84. Antikainen M, Murtomaki S, Syvanne M, et al. 1996. The Gln-Arg191 polymorphism of the human paraoxonase gene (HUMPONA) is not associated with the risk of coronary artery disease in Finns. J. Clin. Invest. 98:833-35
85. Rice G, Ossei-Gerning N, Stickland MH, et al. 1997. The paraoxonase Gln-Arg 192 polymorphism in subjects with ischaemic heart disease. Coron. Artery Dis. 8:677-82
86. Hermann S, Blanc H, Poirier O, et al. 1996. The Gln/Arg polymorphism of human paraoxonase (PON 192) is not related to myocardial infarction in the ECTIM Study. Atherosclerosis 126:299-303
87. Suehiro T, Nakauchi Y, Yamamoto M, et al. 1996. Paraoxonase gene polymorphism in Japanese subjects with coronary heart disease. Int. J. Cardiol. 57:69-73
88. Ombres D, Pannitteri G, Montali A, et al. 1998. The Gln-Arg192 polymorphism of human paraoxonase gene is not associated with coronary artery disease in Italian patients. Arterioscler. Thromb. Vasc. Biol. 18:1611-18
89. Ko YK, Wang SM, Hsu LA, et al. 1998. The Gln-Arg 191 polymorphism of the human paraoxonase gene is not associated with the risk of coronary artery disease among Chinese in Taiwan. Atherosclerosis 141:259-64
90. Cascorbi I, Laule M, Mrozikiewicz PM, et al. 1999. Mutations in the human paraoxonase 1 gene: frequencies, allelic linkages, and association with coronary artery disease. Pharmacogenetics 9:755-61
91. Hasselwander O, Savage DA, McMaster D, et al. 1999. Paraoxonase polymorphisms are not associated with cardiovascular risk in renal transplant recipients. Kidney Int. 56:289-98
92. Aubo C, Senti M, Marrugat J, et al. 2000. Risk of myocardial infarction associated with Gln/Arg 192 polymorphism in the human paraoxonase gene and diabetes mellitus. The REGICOR Investigators. Eur. Heart J. 21:33-38
93. Odawara M, Tachi Y, Yamashita K. 1997. Paraoxonase polymorphism (Gln192-Arg) is not associated with coronary heart disease in Japanese noninsulin-dependent diabetes mellitus. Clin. Endocrinol. Metab. 82:2257-60
94. Sanghera D, Sana N, Kamboh MI. 1998. The codon 55 polymorphism in the paraoxonase 1 gene is not associated with the risk of coronary heart disease in Asian Indians and Chinese. Atherosclerosis 136:217-23
95. Boright A, Connelly PW, Brunt JH, et al. 1998. Genetic variation in paraoxonase-1 and paraoxonase-2 is associated with variation in plasma lipoproteins in Alberta Hutterites. Atherosclerosis 139:131-36
96. Schmidt H, Schmidt R, Niederkorn K, et al. 1998. Paraoxonase PON1 polymorphism leu-met54 is associated with carotid atherosclerosis: results of the Austrian Stroke Prevention Study. Stroke 29:2043-48
97. Ayub A, Mackness MI, Arrol S, et al. 1999. Serum paraoxonase after myocardial infarction. Arterioscler. Thromb. Vasc. Biol. 19:330-35
98. James RW, Leviev I, Ruiz J, et al. 2000. Promoter polymorphism T(-107)C of the paraoxonase PON1 gene is a risk factor for coronary heart disease in type 2 diabetic patients. Diabetes 49:1390-93
99. Jarvik GP, Furlong CE, Hatsukami TS. 2002. Vitamin C and E intake predict increased paraoxonase activity. J. Am. Coll. Cardiol. 39:373B
100. Klose J, Nock C, Hermann M, et al. 2002. Genetic analysis of the mouse brain proteome. Nat. Genet. 30:385-93
101. Clark AG, Weiss KM, Nickerson DA, et al. 1998. Haplotype structure and population genetic inferences from nucleotide-sequence variation in human lipoprotein lipase. Am. J. Hum. Genet. 63:595-612
102. Fullerton SM, Clark AG, Weiss KM, et al. 2000. Apolipoprotein E variation at the sequence haplotype level: implications for the origin and maintenance of a major human polymorphism. Am. J. Hum. Genet. 67:881-900
103. Stephens M, Smith NJ, Donnelly P. 2001. A new statistical method for haplotype reconstruction from population data. Am. J. Hum. Genet. 68:978-89
104. Biggadike K, Angell RM, Burges CM, et al. 2000. Selective plasma hydrolysis of glucocorticoid γ-lactones and cyclic carbonates by the enzyme paraoxonase: an ideal plasma inactivation mechanism. J. Med.Chem. 43:19-21
105. Billecke S, Dragonov D, Counsell R, et al. 2000. Human serum paraoxonase (PON1) isozymes Q and R hydrolyze lactones and cyclic carbonate esters. Drug Metab. Dispos. 28:1335-42
106. Malin R, Laaksonen R, Knuuti J, et al. 2001. Paraoxonase genotype modifies the effect of pravastatin on high-density lipoprotein cholesterol. Pharmacogenetics 11:625-33
107. Tomàs M, Sentì M, Garcia-Faria F, et al. 2000. Effect of simvastatin therapy on paraoxonase activity and related lipoproteins in familial hypercholesterolemic patients. Arterioscler. Thromb. Vasc. Biol. 20:2113-19
108. Leviev I, James R. 2000. Simvastatin increases plasma levels of the antioxidant enzyme paraoxonase by PON1 gene activation. Atherosclerosis 151:41
109. Tougou K, Nakamura A, Watanabe S, et al. 1998. Paraoxonase has a major role in the hydrolysis of prulifloxacin (NM441), a prodrug of a new antibacterial agent. Drug Metab. Dispos. 26:355-59
110. Jakubowski H. 2000. Calcium-dependent human serum homocysteine thiolactone hydrolase: a protective mechanism against protein N-homocysteinylation. J. Biol. Chem. 275:3957-62
111. Playfer JR, Powell C, Evans DA. 1977. Plasma paraoxonase activity in old age. Age Ageing 6:89-95
112. Zech R, Zurcher K. 1974. Organophosphate splitting serum enzymes in different mammals. Comp. Biochem. Physiol. 48:427-33
113. Hernandez AF, Gonzalvo MC, Gil F, et al. 1997. Divergent effects of classical inducers on rat plasma and microsomial fraction paraoxonase and arylesterase. Environ. Toxicol. Pharmacol. 3:83-86
114. Kaliste-Korhonen E, Tuovinen K, Hanninen O. 1998. Effects of phenobarbital and γ-naphtoflavone on activities of different rat esterases after paraoxon exposure. Gen. Pharmacol. 31:307-12
115. Rodrigo L, Hernandez AF, Lopez-Caballero JJ, et al. 2001. Immunohistochemical evidence for the expression and induction of paraoxonase in rat liver, kidney, lung and brain tissue. Implications for its physiological role. Chem. Biol. Interact. 137:123-37
116. Feingold KR, Memon RA, Moser AH, et al. 1998. Paraoxonase activity in the serum and hepatic mRNA levels decrease during the acute phase responses. Atherosclerosis 139:307-15
117. Gonzalvo MC, Gil F, Hernandez AF, et al. 1997. Inhibition of paraoxonase activity in human liver microsomes by exposure to EDTA, metals and mercurials. Chem. Biol. Interact. 105:169-79
118. Cole TB, Li WF, Richter RJ, et al. 2002. Inhibition of paraoxonase (PON1) by heavy metals. Toxicologist 66(1-S): 312
119. Weitman SD, Vodicnick MJ, Lech TJ. 1983. Influence of pregnancy on parathion toxicity and disposition. Toxicol. Appl. Pharmacol. 71:215-24
120. Hasselwander O, McMaster D, Fogarty DG, et al. 1998. Serum paraoxonase and platelet-activating factor acetylhydrolase in chronic renal failure. Clin. Chem. 44:179-81
121. Abbott CA, Mackness MI, Kumar S, et al. 1995. Serum paraoxonase activity, concentration and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. Arterioscler. Thromb. Vasc. Biol. 15:1812-18
122. Mackness MI, Walker CH, Carlson LA. 1987. Low A-esterase activity in serum of patients with fish-eye disease. Clin. Chem. 33:587-88
123. Ferré N, Camps J, Cabré M, et al. 2001. Hepatic paraoxonase activity alterations and free radical production in rats with experimental cirrhosis. Metabolism 50:997-1000
124. Nishio E, Watanabe Y. 1997. Cigarette smoke extract inhibits plasma paraoxonase activity by modification of the enzyme's free thiols. Biochem. Biophys. Res. Commun. 236:289-93
125. James RW, Leviev I, Righetti A. 2000. Smoking is associated with reduced serum paraoxonase activity and concentration in patients with coronary artery disease. Circulation 101:2252-57
126. Jarvik GP, Tsai N, McKinstry LA, et al. 2002. Vitamin C and E intake is associated with increased paraoxonase activity. Arterioscler. Thromb. Vasc. Biol. 22:1329-33
127. Debord J, Dantoine T, Bollinger JC, et al. 1998. Inhibition of arylesterase by aliphatic alcohols. Chem. Biol. Interact. 113:105-15
128. Van der Gaag MS, van Tol A, Scheck LM, et al. 1999. Daily moderate alcohol consumption increases serum paraoxonase activity: a diet-controlled randomized intervention study in middle-aged men. Atherosclerosis 1471:405-10
129. Hayek T, Fuhrman B, Vaja J, et al. 1997. Reduced progression of atherosclerosis in apolipoprotein E-deficient mice following consumption of red wine, or its polyphenol quercetin or catechin, is associated with reduced susceptibility of LDL to oxidation and aggregation. Arterioscler. Thromb. Vasc. Biol. 17:2744-52
130. Aviram M, Dornfeld L, Rosenblat M, et al. 2000. Pomegranate juice consumption reduces oxidative stress, atherogenic modifications to LDL, and platelet aggregation: studies in humans and in atherosclerotic apolipoprotein E-deficient mice. Am. J. Clin. Nutr. 71:1062-76
131. Kaplan M, Hayek T, Raz A, et al. 2001. Pomegranate juice supplementation to atherosclerotic mice reduces macrophage lipid peroxidation, cellular cholesterol accumulation and development of atherosclerosis. J. Nutr. 131:2082-89
132. Kudchodkar BJ, Lacko A, Dory L, et al. 2000. Dietary fat modulates serum paraoxonase 1 activity in rats. J. Nutr. 130:2427-33
133. Wallace AJ, Sutherland WHF, Mann JI, et al. 2001. The effect of meals rich in thermally stressed olive oil and safflower oils on postprandial serum paraoxonase activity in patients with diabetes. Eur. J. Clin. Nutr. 55:951-58
134. Yamada Y, Takatori T, Nagao M, et al. 2001. Expression of paraoxonase isoform did not confer protection from acute sarin poisoning in the Tokyo subway terrorist attack. Int. J. Legal Med. 115:82-84